BVNRY Bavarian Nordic A/S Sponsored ADRs

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark. This is an ADR of a company whose stock trades outside of the U.S. as the symbol DC:BAVA.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$8.62    Pink
As of 03/22/2023     OTCMarkets

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Denmark
Country of incorporation:  Denmark
IPO date:  05/30/2013
Outstanding shares:  212,206,128
Average volume:  12,530
Market cap:   $2,168,746,628
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy